We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...

Novo Nordisk and Eli Lilly (with its Zepbound) are the two reigning kings on the U.S. market these days. There will be more contenders; Viking Therapeutics, in particular, is in the later stages of ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with a ...

Novo Nordisk-aktien stiger markant i tirsdagens aktiehandel og er i skrivende stund oppe med 4,5 pct. Dermed er Novo Nordisk-aktien steget 17 pct. på en uge. »Det er mere end blot ”noget”,« lyder ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

AS Heart Month reminds us of the critical need to protect our cardiovascular and metabolic health, Novo Nordisk Philippines and the Philippine College of Endocrinology, Diabetes and Metabolism (PCEDM) ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

February 18, 2025 Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences ...